The FDA assessed the protection and effectiveness of atidarsagene autotemcel determined by facts from 37 kids who gained atidarsagene autotemcel in two one-arm, open-label medical trials As well as in an expanded access software.[seven] Young children who been given therapy with atidarsagene autotem